Table 2.
Updated phase III randomised trials on hypofractionation for prostate cancer. All results are statistically significant, except those marked with n.s.
| N | Median FU (yrs) | Dose (Gy) per fraction |
Benefit bDFS (%) | Toxicity Gr2 GI (%) |
Toxicity Gr2 GU (%) |
|
|---|---|---|---|---|---|---|
| Dutch trial | ||||||
| Aluwini et al. 2015 | 820 | 5 | 39 × 2 versus 19 × 3.4 | 77 versus 80n.s. | Equal; 13 | 22 versus 23 |
| RTOG 0415 | ||||||
| Lee et al. 2016 | 1092 | 5.8 | 41 × 1.8 versus 28 × 2.5 | 85.3 versus 86.3 | 11.4 versus 18.3 | 20.5 versus 26.2 |
| CHHiP | ||||||
| Dearnaley et al. 2016 | 3163 | 5.1 | 37 × 2 versus 20 × 3 versus 19 × 3 | 88.3 versus 90.6 versus 85.9 | Equal; 2n.s. | 11 versus 13n.s. |
bDFS: biochemical disease-free survival; CHHiP: conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer; n.s.: not significant; Gr2: grade 2 or more toxicity.